(27 days)
MQV, MBP
Not Found
No
The summary describes a bone graft material and does not mention any AI or ML capabilities.
Yes
The device is a bone graft material intended to fill bony voids or gaps, which directly addresses a physiological condition (bone defects) and aids in healing, consistent with the definition of a therapeutic device.
No
This device is a bone graft material intended to fill bony voids or gaps, not to diagnose medical conditions or provide diagnostic information.
No
The device is described as a bone graft material provided as physical pellets, indicating it is a hardware device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that OSTEOSET® DBM Pellets are a bone graft material used to fill bony voids or gaps in the skeletal system. This is a therapeutic use, not a diagnostic one.
- Device Description: The description reinforces that it's a bone graft material designed to be implanted and resorbed.
- Lack of Diagnostic Function: There is no mention of the device being used to test samples (like blood, urine, or tissue) or to provide information about a patient's health status or condition.
IVD devices are used to perform tests on samples taken from the human body to provide information for diagnosis, monitoring, or screening. This device does not fit that description.
N/A
Intended Use / Indications for Use
OSTEOSET® DBM Pellets are indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. OSTEOSET® DBM Pellets are intended to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine, and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone.
Product codes
MQV, MBP
Device Description
OSTEOSET® DBM Pellets are a bone graft material. OSTEOSET® DBM Pellets combine the effects of DBM and OSTEOSET® Pellets. The DBM used in OSTEOSET® DBM Pellets is tested to confirm the osteoinductivity of each DBM lot.
OSTEOSET® DBM Pellets are provided as preformed 3.0 mm or 4.8 mm pellets. The biodegradable, radiopaque pellets are used to fill bone voids and are resorbed in approximately 30-60 days when used according to labeling. This product is supplied sterile for single patient use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skeletal system (i.e., the extremities, spine, and pelvis)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Osteoinductivity Potential Testing: Each lot of demineralized bone matrix (DBM) incorporated into OSTEOSET® DBM Pellets is assayed using either of the following two test methods: 1) in vitro assay using human bone forming cells, which was correlated to the athymic rat model and clinical results of the assayed DBM. OR 2) in vitro assay for a native protein (BMP-2) as a surrogate test marker for osteoinductive potential. Results from this immunoassay were correlated to the athymic rat model. Testing each lot of DBM with this cell-based bioassay (1) or immunoassay (2) assures that only DBM with osteoinductive potential is used in the OSTEOSET® DBM Pellets.
Viral Inactivation Potential: The method for processing the DBM contained in OSTEOSET®DBM Pellets was evaluated for its viral inactivation potential. A panel of model potential human viruses representing various virus types, sizes, shapes, and genomes were evaluated. The viral inactivation testing demonstrated suitable viral inactivation potential of the processing method for a wide spectrum of potential human viruses.
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
JAN 2 6 2006
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CRF 807, this information serves as a Summary of Safety and Effectiveness for the use of the OSTEOSET® DBM Pellets.
| Submitted By: | Wright Medical Technology, Inc. |
|---|---|
| Date: | December 29, 2005 |
| Contact Person: | Theresa Leister |
| Regulatory Affairs Specialist | |
| Proprietary Name: | OSTEOSET® DBM Pellets |
| Common Name: | Bone Void Filler |
| Classification Name and Reference: | 888.3045 - Resorbable Calcium Salt Bone Void |
| Filler Device (Class II) | |
| Device Product Code and Panel Code: | Orthopedics/87/MQV |
DEVICE INFORMATION
A. INTENDED USE
OSTEOSET® DBM Pellets are indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. OSTEOSET® DBM Pellets are intended to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine, and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone.
B. DEVICE DESCRIPTION
OSTEOSET® DBM Pellets are a bone graft material. OSTEOSET® DBM Pellets combine the effects of DBM and OSTEOSET® Pellets. The DBM used in OSTEOSET® DBM Pellets is tested to confirm the osteoinductivity of each DBM lot.
OSTEOSET® DBM Pellets are provided as preformed 3.0 mm or 4.8 mm pellets. The biodegradable, radiopaque pellets are used to fill bone voids and are resorbed in approximately 30-60 days when used according to labeling. This product is supplied sterile for single patient use.
1
C. SUBSTANTIAL EQUIVALENCE INFORMATION
The indications for use and design features of OSTEOSET® DBM Pellets are identical to those of the predicate device. The fundamental scientific technology of the modified device has not changed relative to the predicate device. The safety and effectiveness of the OSTEOSET® DBM Pellets are adequately supported by the substantial equivalence information, materials information, and analysis data provided within this Premarket Notification.
Osteoinductivity Potential Testing
Each lot of demineralized bone matrix (DBM) incorporated into OSTEOSET® DBM Pellets is assayed using either of the following two test methods:
-
- in vitro assay using human bone forming cells', which was correlated to the athymic rat model4 and clinical results of the assayed DBM'. OR
-
- in vitro assay for a native protein (BMP-2) as a surrogate test marker for osteoinductive potential . Results from this immunoassay were correlated to the athymic rat model 3. Although only one native protein is used as the test marker, it is the combination of various proteins that is responsible for its osteoinductive potential.
Testing each lot of DBM with this cell-based bioassay (1) or immunoassay (2) assures that only DBM with osteoinductive potential is used in the OSTEOSET® DBM Pellets.
The osteoinductivity of this combination of DBM and calcium sulfate (OSTEOSET® Pellets) has not been established; therefore, it is unknown to what extent the formulation components may alter the osteoinductive character of the DBM. Additionally, it is unknown how osteoinductivity of the DBM component, measured via either in vitro assay, will correlate with human clinical performance of OSTEOSET® DBM Pellets.
Viral Inactivation Potential
The method for processing the DBM contained in OSTEOSET®DBM Pellets was evaluated for its viral inactivation potential. A panel of model potential human viruses representing various virus types, sizes, shapes, and genomes were evaluated. The viral inactivation testing demonstrated suitable viral inactivation potential of the processing method for a wide spectrum of potential human viruses.
-
Wikins, R.M. (1999) Clinical Effectiveness of Demineralized Bone Matrix Assayed in Human Cell Culture Advances in Tissue l . Banking. 3:113-124.
This study correlated the results from the in vitro bioassay to results in the athymic rat model and clinical results of the DBM. -
- Lindholm TS, Urist MR. A quantiative analysis of new bone formation in compositive grafts of bone marrow and bone matrix. Clin Orthop 1980 Jul-Aug.(150):288-300
-
- Data on file at Wright Medical Technology, Inc.
2
Image /page/2/Picture/1 description: The image is a black and white logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three curved lines representing its wings and body. The eagle is facing to the right. The text "DEPARTMENT OF HEALTH AND HUMAN SERVICES, USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JAN 2 6 2006
Ms. Theresa Leister Regulatory Affairs Specialist Wright Medical Technologies, Inc. 5677 Airline Road Arlington, Tennessee 38002
Re: K053642
Trade/Device Name: OSTEOSET® DBM Pellets Regulation Number: 21 CFR 888.3045 Regulation Name: filler, bone void, osteoinduction (without human growth factor) Regulatory Class: Class II Product Code: MBP and MQV Dated: December 29, 2005 Received: December 30, 2005
Dear Ms. Leister:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
3
Page 2 - Theresa Leister
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
C. Mark N. Mollenkamp, M.S.
Mark N. Melkerson, M.S. Acting Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K053642
Device Name: OSTEOSET® DBM Pellets
Indications For Use:
OSTEOSET® DBM Pellets are indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. OSTEOSET® DBM Pellets are intended to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine, and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Page 1 of 1
(Division Sign-Off) Division of General, Restorative, and Neurological Devices
510(k) Number (053642